货号价格

MHC-HM418-100μg / 询价

MHC-HM418-500μg / 询价

MHC-HM418-1mg / 询价

Human KRAS G12V (HLA-A*03:01) Complex Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human KRAS G12V (HLA-A*03:01) Complex Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M) and VVVGAVGVGK peptide.[Accession | NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVGAVGVGK]

分子量大小(Molecular Weight)

The protein has a predicted MW of 50.2 kDa. Due to glycosylation, the protein migrates to 55-60 kDa based on Tris-Bis PAGE result.

内毒素(Endotoxin)

Less than 1EU per ug by the LAL method.

纯度(Purity)

> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended (usually we use 1mg/ml solution for lyophilization). Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-20 to -80°C for 3-6 months in unopened state after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please avoid freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Human KRAS G12V (HLA-A*03:01) Complex on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

The purity of Human KRAS G12V (HLA-A*03:01) Complex is greater than 95% as determined by SEC-HPLC.

SPR Data

Human KRAS G12V (HLA-A*03:01) Complex, His Tag captured on CM5 Chip via Anti-His Antibody can bind Anti-KRAS G12V (HLA-A*03:01) Antibody with an affinity constant of 0.205μM as determined in SPR assay (Biacore T200).

背景(Background)

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

分子别名(Synonyms)

MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD

文献(References)

(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.

恺佧生物科技(上海)有限公司
电话:400-614-0008
地址:上海市浦江高科技园新骏环路188号8A区四楼
在线留言